Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target

by Dhanusha Sabanathan, Maria E. Lund, Douglas H. Campbell, Bradley J. Walsh, Howard Gurney
Published 2021-10-01

A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells

by Maria E. Lund, Christopher B. Howard, Kristofer J. Thurecht, Douglas H. Campbell, Stephen M. Mahler, Bradley J. Walsh
Published 2020-12-01

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.

by Douglas H Campbell, Maria E Lund, Aline L Nocon, Paul J Cozzi, Mark Frydenberg, Paul De Souza, Belinda Schiller, Jennifer L Beebe-Dimmer, Julie J Ruterbusch, Bradley J Walsh
Published 2018-01-01

Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab^®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery

by Dmitry M. Polikarpov, Douglas H. Campbell, Lucinda S. McRobb, Jiehua Wu, Maria E. Lund, Yanling Lu, Sergey M. Deyev, Andrew S. Davidson, Bradley J. Walsh, Andrei V. Zvyagin, David A. Gillatt
Published 2020-04-01

Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1)

by Mei-Chun Yeh, Brian W. C. Tse, Nicholas L. Fletcher, Zachary H. Houston, Maria Lund, Marianna Volpert, Chelsea Stewart, Kamil A. Sokolowski, Varinder Jeet, Kristofer J. Thurecht, Douglas H. Campbell, Bradley J. Walsh, Colleen C. Nelson, Pamela J. Russell
Published 2020-05-01